Moderna Cash Flow Statement
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Moderna free cash flow
In fiscal 2025, Moderna generated -$1.87 billion of operating cash flow and spent $192.0 million on capital expenditures. That left free cash flow of -$2.06 billion, a free-cash-flow margin of -106.2% of revenue. Moderna returned $2.0 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
Moderna cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -2.82B | -3.56B | -4.71B | 8.36B | 12.20B | -747.00M | -514.00M | -384.73M | -255.92M | -216.21M |
| Net Income growth (YoY) | — | — | -156.37% | -31.47% | — | — | — | — | — | — |
| Depreciation & Amortization | 211.00M | 185.00M | 617.00M | 348.00M | 232.00M | 31.00M | 31.00M | 24.86M | 20.54M | 15.11M |
| Stock-Based Compensation | 483.00M | 429.00M | 305.00M | 226.00M | 142.00M | 93.00M | 81.00M | 72.56M | 40.05M | 39.36M |
| Change in Working Capital | 218.00M | 332.00M | 1.08B | -4.63B | -516.00M | 2.19B | -57.00M | -53.79M | -173.18M | 155.57M |
| Operating Cash Flow | -1.87B | -3.00B | -3.12B | 4.98B | 13.62B | 2.03B | -459.00M | -330.87M | -331.48M | 66.73M |
| Capital Expenditures | -192.00M | -1.05B | -707.00M | -400.00M | -284.00M | -68.00M | -32.00M | -105.77M | -58.40M | -33.14M |
| Investing Cash Flow | 1.95B | 1.95B | 4.21B | -5.18B | -8.52B | -1.67B | -15.00M | -373.09M | 417.36M | -648.61M |
| Share Repurchases | -2.00M | 0 | -1.15B | -3.33B | -857.00M | 0 | 0 | — | — | — |
| Financing Cash Flow | 593.00M | 56.00M | -1.38B | -3.45B | -873.00M | 2.03B | 52.00M | 1.23B | 168.00K | 472.91M |
| Net Change in Cash | 668.00M | -999.00M | -289.00M | -3.64B | 4.22B | 2.39B | -422.00M | 522.88M | 86.05M | -108.96M |
| Free Cash Flow | -2.06B | -4.05B | -3.83B | 4.58B | 13.34B | 1.96B | -491.00M | -436.63M | -389.88M | 33.59M |
This table shows 10 annual periods of Moderna's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MRNA's reporting calendar. What is a cash flow statement?